IDH1 and cholangiocarcinoma: Current targeted inhibitors (AG120 and IDH305) of IDH1 mutation can selectively inhibit mutant IDH protein, which were used to further verify the effects of IDH1 mutation on erastin-induced ferroptosis in cholangiocarcinoma.